Pozdniakova N, Lipengolts A, Skribitsky V, Shpakova K, Finogenova Y, Smirnova A
Int J Mol Sci. 2024; 25(18).
PMID: 39337680
PMC: 11432708.
DOI: 10.3390/ijms251810197.
Krawczynska N, Wang Y, Lim K, Das Gupta A, Lenczowski A, Abughazaleh M
bioRxiv. 2024; .
PMID: 39131340
PMC: 11312600.
DOI: 10.1101/2024.08.02.606061.
Pedram K, Shon D, Tender G, Mantuano N, Northey J, Metcalf K
Nat Biotechnol. 2023; 42(4):597-607.
PMID: 37537499
PMC: 11018308.
DOI: 10.1038/s41587-023-01840-6.
Mas-Rosario J, Medor J, Jeffway M, Martinez-Montes J, Farkas M
Front Oncol. 2023; 13:1151384.
PMID: 37091169
PMC: 10113556.
DOI: 10.3389/fonc.2023.1151384.
Turrell F, Orha R, Guppy N, Gillespie A, Guelbert M, Starling C
Nat Cancer. 2023; 4(4):468-484.
PMID: 36914817
PMC: 10132974.
DOI: 10.1038/s43018-023-00525-y.
Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs.
Nel A, Mei K, Liao Y, Liu X
ACS Nano. 2022; 16(4):5184-5232.
PMID: 35348320
PMC: 9519818.
DOI: 10.1021/acsnano.2c01252.
Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing.
Wolfson B, Padget M, Schlom J, Hodge J
J Immunother Cancer. 2021; 9(7).
PMID: 34244306
PMC: 8268928.
DOI: 10.1136/jitc-2020-002258.
Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge.
Bushnell G, Deshmukh A, den Hollander P, Luo M, Soundararajan R, Jia D
NPJ Breast Cancer. 2021; 7(1):66.
PMID: 34050189
PMC: 8163741.
DOI: 10.1038/s41523-021-00269-x.
Hyperglycemia-Induced miR-467 Drives Tumor Inflammation and Growth in Breast Cancer.
Gajeton J, Krukovets I, Muppala S, Verbovetskiy D, Zhang J, Stenina-Adognravi O
Cancers (Basel). 2021; 13(6).
PMID: 33809756
PMC: 8002237.
DOI: 10.3390/cancers13061346.
An Immunoregulatory Role for Complement Receptors in Murine Models of Breast Cancer.
Nadia Md Akhir F, Mohd Noor M, Leong K, Nabizadeh J, Manthey H, Sonderegger S
Antibodies (Basel). 2021; 10(1).
PMID: 33430104
PMC: 7838807.
DOI: 10.3390/antib10010002.
Formulation of objective indices to quantify machine failure risk analysis for interruptions in radiotherapy.
Kawahara D, Nakano H, Saito A, Ochi Y, Nagata Y
J Appl Clin Med Phys. 2020; 22(1):165-173.
PMID: 33326695
PMC: 7856522.
DOI: 10.1002/acm2.13126.
Targeted glycan degradation potentiates the anticancer immune response in vivo.
Gray M, Stanczak M, Mantuano N, Xiao H, Pijnenborg J, Malaker S
Nat Chem Biol. 2020; 16(12):1376-1384.
PMID: 32807964
PMC: 7727925.
DOI: 10.1038/s41589-020-0622-x.
Immunization associated with primary tumor growth leads to rejection of commonly used syngeneic tumors upon tumor rechallenge.
Alicke B, Totpal K, Schartner J, Berkley A, Lehar S, Capietto A
J Immunother Cancer. 2020; 8(2).
PMID: 32675310
PMC: 7368499.
DOI: 10.1136/jitc-2020-000532.
Breast cancer animal models and applications.
Zeng L, Li W, Chen C
Zool Res. 2020; 41(5):477-494.
PMID: 32629551
PMC: 7475017.
DOI: 10.24272/j.issn.2095-8137.2020.095.
Chemerin Suppresses Breast Cancer Growth by Recruiting Immune Effector Cells Into the Tumor Microenvironment.
Pachynski R, Wang P, Salazar N, Zheng Y, Nease L, Rosalez J
Front Immunol. 2019; 10:983.
PMID: 31139180
PMC: 6518384.
DOI: 10.3389/fimmu.2019.00983.
Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines.
Ravindranathan S, Nguyen K, Kurtz S, Frazier H, Smith S, Koppolu B
Breast Cancer Res. 2018; 20(1):126.
PMID: 30348199
PMC: 6198508.
DOI: 10.1186/s13058-018-1054-3.
Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis.
Yang Y, Yang H, Hu Y, Watson P, Liu H, Geiger T
Oncotarget. 2017; 8(19):30621-30643.
PMID: 28430642
PMC: 5458155.
DOI: 10.18632/oncotarget.15695.
Redshifted Cherenkov Radiation for in vivo Imaging: Coupling Cherenkov Radiation Energy Transfer to multiple Förster Resonance Energy Transfers.
Bernhard Y, Collin B, Decreau R
Sci Rep. 2017; 7:45063.
PMID: 28338043
PMC: 5364485.
DOI: 10.1038/srep45063.
Murine model of chemotherapy-induced extraintestinal pathogenic Escherichia coli translocation.
Green S, Ajami N, Ma L, Poole N, Price R, Petrosino J
Infect Immun. 2015; 83(8):3243-56.
PMID: 26034214
PMC: 4496622.
DOI: 10.1128/IAI.00684-15.
Inhibition of hyperglycemia-induced angiogenesis and breast cancer tumor growth by systemic injection of microRNA-467 antagonist.
Krukovets I, Legerski M, Sul P, Stenina-Adognravi O
FASEB J. 2015; 29(9):3726-36.
PMID: 26018675
PMC: 4550367.
DOI: 10.1096/fj.14-267799.
